The materialisation of the idea of interfering with expressions/activities of specific Bcl-2 targets in cancerous cells challenges us to develop a complete understanding of the behaviour of Bcl-2 proteins in response to different anticancer agents in various neoplasms. Here, BCL2 is linked to neoplasm.